Developer docs
API playgroundTry for free, no card

Search company profiles

Veritas Genetics

Full company profile

uuid0002ysm

Namestring
Veritas Genetics
Legal namestring
Veritas Intercontinental
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Veritas Genetics, operating under the legal entity Veritas Intercontinental (incorporated in Madrid, Spain; CIF B88132907), is a private genetic testing company founded in 2014 that provides whole-genome and whole-exome sequencing services to consumers, clinicians, and health systems across more than 11 markets including the US, UK, Spain, Italy, Portugal, Brazil, Colombia, Ecuador, Mexico, Argentina, and the UAE. Its product portfolio is organised into four pillars — Preventive Medicine (myGenome, myGeneticRisk, myHealthScore, myPharma), Perinatal Medicine (myPrenatal, myNewborn, myBabyHealth, qCarrier, PregnancyLoss, PrenatalWES, ArrayCGH Prenatal, ThromboRisk), Diagnostic Genomics (CardioRisk, CancerRisk, GenomeDx, ExomeDx, Targeted Panels), and mandatory Genetic Counselling — with all tests requiring physician-assisted pre- and post-test counselling.

The core technology is Next-Generation Sequencing-based whole-genome and whole-exome analysis paired with advanced bioinformatics and geneticist-led variant validation, delivered through the proprietary myGenome patient-ready reporting platform. The company's commercial model is a hybrid direct-to-consumer and B2B/clinical channel: consumers request tests via the corporate website, physicians prescribe and interpret results, and genetic counsellors (in-house or partner) handle pre- and post-test engagement. In March 2026 Veritas joined an Illumina-led consortium with Fuze Health to channel preventive genomics through health-insurance plans in the US and globally, while in September 2025 it acquired Barcelona-based qGenomics to deepen clinical-diagnostics capability and European reach. Revenue is generated through one-time test fees rather than recurring subscriptions, with no publicly disclosed pricing.

Short descriptiontext

Veritas Genetics is a private Spanish-incorporated genetic testing company that provides whole-genome and whole-exome sequencing services — organised into preventive, perinatal, and diagnostic portfolios — to consumers, clinicians, and health insurers across 11+ markets, with mandatory physician-assisted genetic counselling.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersDanvers, United States
HQ citystring
Danvers
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
genetic testing services, whole genome sequencing, preventive genomics, prenatal genetic screening, hereditary cancer diagnostics
Industry4 codes
PRIMARYHLAFAMAH
Genetic & Prenatal Testing Laboratories
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
NAICS code2 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories62151
SIC code2 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Genetic Testing Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Genetic Testing Services
TypeOne Time License
Description

One-time genetic testing services based on whole genome and exome sequencing, with genetic counseling included. Tests include myGenome, myPrenatal, myNewborn, diagnostic panels, and pharmacogenomic testing.

veritasint.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Brand1 of 12 records shown
1myGenome
Description

Whole genome sequencing service for disease prevention and healthcare

veritasint.com
+11 more records
Core offering1 text field

Veritas Genetics provides clinical genetic testing services built on whole genome and whole exome sequencing using Next Generation Sequencing technology. Its flagship myGenome platform translates complete DNA data into clinically relevant disease-risk, polygenic-risk, and pharmacogenomic reports, supported by mandatory pre- and post-test genetic counseling delivered with physician oversight across preventive, perinatal, and diagnostic use cases.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 17% of people have genetic variants that increase disease risk
+5 more records
Product overview1 text field

Veritas Genetics (operating as Veritas Intercontinental) is a genetic testing company offering a unified platform of whole-genome and whole-exome sequencing services organized into four portfolio areas: Preventive Medicine, Perinatal Medicine, Diagnostic Genomics, and Genetic Counseling. The core technology is whole-genome sequencing (WGS), which generates complete DNA data that can be reanalysed over time. The flagship consumer product is myGenome, which bundles disease risk assessment, polygenic risk screening, and pharmacogenomic reporting. The perinatal portfolio spans myPrenatal (non-invasive prenatal screening), myNewborn, myBabyHealth, qCarrier, PregnancyLoss, PrenatalWES, ArrayCGH Prenatal, and ThromboRisk. The diagnostic genomics portfolio includes CardioRisk, CancerRisk, GenomeDx, ExomeDx, and Targeted Panels. Genetic Counselling is a mandatory support service across all products. The company also operates the Veritas Academy educational platform. The portfolio architecture is a single technology base (WGS/WES) with multiple disease-domain overlays, all requiring physician-assisted genetic counseling.

Product and service1 record
1myGenome
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-03-16
Description

Illumina and Veritas Genetics formed a strategic consortium to integrate preventive genomics into routine healthcare through health insurance programs in the United States and global markets. The partnership combines whole-genome sequencing, advanced informatics, and patient-ready genomic reporting through Veritas' myGenome platform to enable earlier identification of disease risks such as hereditary cancers and cardiometabolic conditions. The consortium also aims to generate a consented clinical-genomics dataset supporting research partnerships across the precision medicine ecosystem.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-16
Description

Part of the Illumina consortium arrangement where Fuze Health collaborates with Veritas Genetics to integrate whole-genome sequencing into preventive healthcare via insurance plans, enabling population-scale genomics programs.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-17
Description

Veritas Genetics acquired qGenomics, a biotech company based in Barcelona, Spain, for an undisclosed amount. The acquisition aims to expand Veritas Genetics' capabilities in genomics diagnostics, with a focus on clinical applications and European market presence.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical genetic testing company specializing in reproductive health (non-invasive prenatal screening), oncology, and organ transplant monitoring. Directly comparable to Veritas's myPrenatal and broader perinatal medicine portfolio.

TypeDirect peer
Description

Whole genome sequencing platform with a population health and health system focus. Closest technology peer to Veritas given shared WGS-based architecture and emphasis on reanalysis over time; comparable population genomics and payer strategy.

TypeDirect peer
Description

Established molecular diagnostics company with leading hereditary cancer testing (BRACAnalysis) and broader women's health, oncology, and mental health portfolios. Comparable to Veritas's CancerRisk and pharmacogenomic offerings, though operating at substantially larger scale as a public company.

TypeDirect peer
Description

Direct-to-consumer genetic testing company offering ancestry, health risk, and carrier screening. Most directly comparable peer given Veritas's DTC motion, though 23andMe uses genotyping arrays rather than WGS, and has experienced significant business and data-privacy setbacks that frame the broader category's risk profile.

TypeDirect peer
Description

Clinical genetics laboratory offering hereditary cancer, reproductive, and rare disease testing across a broad test menu. Comparable to Veritas's diagnostic genomics portfolio (CancerRisk, CardioRisk, GenomeDx) and operates in similar reimbursement-driven clinical channels.

TypeDirect peer
Description

Direct-to-consumer whole genome sequencing company founded by George Church. Closest technology peer to Veritas given its WGS-first model, though Nebula is more consumer-focused and lacks the diagnostic/clinical breadth of Veritas's portfolio.

TypeDirect peer
Description

Clinical genomics laboratory specializing in whole exome and genome sequencing for rare disease and pediatric diagnosis. Directly comparable to Veritas's GenomeDx and ExomeDx diagnostic products.

TypeBroad incumbent
Description

Large US clinical laboratory offering an extensive genetic and molecular diagnostics menu including non-invasive prenatal screening and hereditary cancer panels. Comparable as a competing channel for physicians ordering genetic tests, though Quest operates across far broader laboratory categories.

TypeBroad incumbent
Description

Major clinical laboratory network offering women's health, oncology, and genetic testing including through its acquisition of Invitae. Comparable as a broad clinical laboratory competitor with established physician relationships and reimbursement infrastructure that smaller genetic testing specialists must compete against.

TypeDirect peer
Description

Clinical and population-scale genetic testing company offering hereditary cancer, cardiovascular, and pharmacogenomic tests with a strong employer/payer channel. Highly comparable to Veritas's preventive genomics offering, including a similar push into insurance and population health programs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Veritas Genetics

Genetic Testing Servicesveritasgenetics.com

Veritas Genetics is a private Spanish-incorporated genetic testing company that provides whole-genome and whole-exome sequencing services — organised into preventive, perinatal, and diagnostic portfolios — to consumers, clinicians, and health insurers across 11+ markets, with mandatory physician-assisted genetic counselling.

What Veritas Genetics does

Veritas Genetics, operating under the legal entity Veritas Intercontinental (incorporated in Madrid, Spain; CIF B88132907), is a private genetic testing company founded in 2014 that provides whole-genome and whole-exome sequencing services to consumers, clinicians, and health systems across more than 11 markets including the US, UK, Spain, Italy, Portugal, Brazil, Colombia, Ecuador, Mexico, Argentina, and the UAE. Its product portfolio is organised into four pillars — Preventive Medicine (myGenome, myGeneticRisk, myHealthScore, myPharma), Perinatal Medicine (myPrenatal, myNewborn, myBabyHealth, qCarrier, PregnancyLoss, PrenatalWES, ArrayCGH Prenatal, ThromboRisk), Diagnostic Genomics (CardioRisk, CancerRisk, GenomeDx, ExomeDx, Targeted Panels), and mandatory Genetic Counselling — with all tests requiring physician-assisted pre- and post-test counselling.

The core technology is Next-Generation Sequencing-based whole-genome and whole-exome analysis paired with advanced bioinformatics and geneticist-led variant validation, delivered through the proprietary myGenome patient-ready reporting platform. The company's commercial model is a hybrid direct-to-consumer and B2B/clinical channel: consumers request tests via the corporate website, physicians prescribe and interpret results, and genetic counsellors (in-house or partner) handle pre- and post-test engagement. In March 2026 Veritas joined an Illumina-led consortium with Fuze Health to channel preventive genomics through health-insurance plans in the US and globally, while in September 2025 it acquired Barcelona-based qGenomics to deepen clinical-diagnostics capability and European reach. Revenue is generated through one-time test fees rather than recurring subscriptions, with no publicly disclosed pricing.

Veritas Genetics firmographics

Firmographics
Name
Veritas Genetics
Legal name
Veritas Intercontinental
Website
https://veritasgenetics.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
51–100 employees
Short description
Veritas Genetics is a private Spanish-incorporated genetic testing company that provides whole-genome and whole-exome sequencing services — organised into preventive, perinatal, and diagnostic portfolios — to consumers, clinicians, and health insurers across 11+ markets, with mandatory physician-assisted genetic counselling.
Ownership category
akta.pro rank

Veritas Genetics industry classification

Industry
Product category
Genetic Testing Services
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAFAMAH
Genetic & Prenatal Testing Laboratories
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)

Keywords

  • Genetic testing services
  • Whole genome sequencing
  • Preventive genomics
  • Prenatal genetic screening
  • Hereditary cancer diagnostics

Where Veritas Genetics is headquartered

Location

Headquarters

HQ city
Danvers
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Veritas Genetics business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Genetic Testing Services: One-time genetic testing services based on whole genome and exome sequencing, with genetic counseling included. Tests include myGenome, myPrenatal, myNewborn, diagnostic panels, and pharmacogenomic testing.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Veritas Genetics product offering

Product offering

Core offering

Veritas Genetics provides clinical genetic testing services built on whole genome and whole exome sequencing using Next Generation Sequencing technology. Its flagship myGenome platform translates complete DNA data into clinically relevant disease-risk, polygenic-risk, and pharmacogenomic reports, supported by mandatory pre- and post-test genetic counseling delivered with physician oversight across preventive, perinatal, and diagnostic use cases.

Product overview

Veritas Genetics (operating as Veritas Intercontinental) is a genetic testing company offering a unified platform of whole-genome and whole-exome sequencing services organized into four portfolio areas: Preventive Medicine, Perinatal Medicine, Diagnostic Genomics, and Genetic Counseling. The core technology is whole-genome sequencing (WGS), which generates complete DNA data that can be reanalysed over time. The flagship consumer product is myGenome, which bundles disease risk assessment, polygenic risk screening, and pharmacogenomic reporting. The perinatal portfolio spans myPrenatal (non-invasive prenatal screening), myNewborn, myBabyHealth, qCarrier, PregnancyLoss, PrenatalWES, ArrayCGH Prenatal, and ThromboRisk. The diagnostic genomics portfolio includes CardioRisk, CancerRisk, GenomeDx, ExomeDx, and Targeted Panels. Genetic Counselling is a mandatory support service across all products. The company also operates the Veritas Academy educational platform. The portfolio architecture is a single technology base (WGS/WES) with multiple disease-domain overlays, all requiring physician-assisted genetic counseling.

Differentiator

Problem solved

Functional benefit

Brands

  • myGenome: Whole genome sequencing service for disease prevention and healthcare
  • myGeneticRisk
  • myHealthScore
  • myPharma
  • myPrenatal
  • myNewborn
  • myBabyHealth
  • qCarrier
  • CardioRisk
  • CancerRisk
  • GenomeDx
  • ExomeDx

Products and services

  • myGenome

Quantifiable outcome

  • 17% of people have genetic variants that increase disease risk
  • +5 more outcomes

Companies that use Veritas Genetics

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Veritas Genetics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Veritas Genetics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered flagship and core.

  • Illumina Inc.flagshipStrategic or Co-development Partner · 16 March 2026Illumina and Veritas Genetics formed a strategic consortium to integrate preventive genomics into routine healthcare through health insurance programs in the United States and global markets. The partnership combines whole-genome sequencing, advanced informatics, and patient-ready genomic reporting through Veritas' myGenome platform to enable earlier identification of disease risks such as hereditary cancers and cardiometabolic conditions. The consortium also aims to generate a consented clinical-genomics dataset supporting research partnerships across the precision medicine ecosystem.
  • Fuze HealthcoreStrategic or Co-development Partner · 16 March 2026Part of the Illumina consortium arrangement where Fuze Health collaborates with Veritas Genetics to integrate whole-genome sequencing into preventive healthcare via insurance plans, enabling population-scale genomics programs.
  • qGenomicscoreStrategic or Co-development Partner · 17 September 2025Veritas Genetics acquired qGenomics, a biotech company based in Barcelona, Spain, for an undisclosed amount. The acquisition aims to expand Veritas Genetics' capabilities in genomics diagnostics, with a focus on clinical applications and European market presence.

Scale indicators1 record

Recent moves6 records

Expansion highlights6 records

Veritas Genetics competitors and assessment

Company assessment

Direct peers

  • Natera: Clinical genetic testing company specializing in reproductive health (non-invasive prenatal screening), oncology, and organ transplant monitoring. Directly comparable to Veritas's myPrenatal and broader perinatal medicine portfolio.
  • Helix: Whole genome sequencing platform with a population health and health system focus. Closest technology peer to Veritas given shared WGS-based architecture and emphasis on reanalysis over time; comparable population genomics and payer strategy.
  • Myriad Genetics: Established molecular diagnostics company with leading hereditary cancer testing (BRACAnalysis) and broader women's health, oncology, and mental health portfolios. Comparable to Veritas's CancerRisk and pharmacogenomic offerings, though operating at substantially larger scale as a public company.
  • 23andMe: Direct-to-consumer genetic testing company offering ancestry, health risk, and carrier screening. Most directly comparable peer given Veritas's DTC motion, though 23andMe uses genotyping arrays rather than WGS, and has experienced significant business and data-privacy setbacks that frame the broader category's risk profile.
  • Invitae: Clinical genetics laboratory offering hereditary cancer, reproductive, and rare disease testing across a broad test menu. Comparable to Veritas's diagnostic genomics portfolio (CancerRisk, CardioRisk, GenomeDx) and operates in similar reimbursement-driven clinical channels.
  • Nebula Genomics: Direct-to-consumer whole genome sequencing company founded by George Church. Closest technology peer to Veritas given its WGS-first model, though Nebula is more consumer-focused and lacks the diagnostic/clinical breadth of Veritas's portfolio.
  • GeneDx: Clinical genomics laboratory specializing in whole exome and genome sequencing for rare disease and pediatric diagnosis. Directly comparable to Veritas's GenomeDx and ExomeDx diagnostic products.
  • Color Genomics: Clinical and population-scale genetic testing company offering hereditary cancer, cardiovascular, and pharmacogenomic tests with a strong employer/payer channel. Highly comparable to Veritas's preventive genomics offering, including a similar push into insurance and population health programs.

Broad incumbents

  • Quest Diagnostics: Large US clinical laboratory offering an extensive genetic and molecular diagnostics menu including non-invasive prenatal screening and hereditary cancer panels. Comparable as a competing channel for physicians ordering genetic tests, though Quest operates across far broader laboratory categories.
  • Laboratory Corporation of America (Labcorp): Major clinical laboratory network offering women's health, oncology, and genetic testing including through its acquisition of Invitae. Comparable as a broad clinical laboratory competitor with established physician relationships and reimbursement infrastructure that smaller genetic testing specialists must compete against.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Veritas Genetics social profiles

Digital presence

Veritas Genetics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Veritas Genetics leadership team

Management profile

Number of profiles

Profiles4 records

Veritas Genetics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Veritas Genetics funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Veritas Genetics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Veritas Genetics

What does Veritas Genetics do?

Veritas Genetics provides clinical genetic testing services built on whole genome and whole exome sequencing using Next Generation Sequencing technology. Its flagship myGenome platform translates complete DNA data into clinically relevant disease-risk, polygenic-risk, and pharmacogenomic reports, supported by mandatory pre- and post-test genetic counseling delivered with physician oversight across preventive, perinatal, and diagnostic use cases.

Is Veritas Genetics a public or private company?

Veritas Genetics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Veritas Genetics founded?

Veritas Genetics was founded in 2014. It employs 51 to 100 people.

Where is Veritas Genetics based?

Veritas Genetics is headquartered in Danvers, United States, in the North America region.

How does Veritas Genetics make money?

One revenue line is on record: genetic Testing Services.

Who are Veritas Genetics's main competitors?

Direct peers on record are Natera, Helix, Myriad Genetics, 23andMe, Invitae, Nebula Genomics, GeneDx and Color Genomics. Broad incumbents are Quest Diagnostics and Laboratory Corporation of America (Labcorp).

Does Veritas Genetics have an API?

No public API is recorded for Veritas Genetics.

What industry is Veritas Genetics in?

Veritas Genetics's product category is Genetic Testing Services. Its primary akta.pro industry code is HLAFAMAH, Genetic & Prenatal Testing Laboratories, with a secondary code of HLAFAMAE, Molecular Diagnostics & Genomics Laboratories. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
National TodayIllumina partners with Veritas Genetics to advance preventive genomicsIllumina and Veritas Genetics announced a strategic collaboration on March 16, 2026, to integrate preventive genomics into everyday healthcare primarily in the United States and other global markets. The partnership aims to develop an integrated data ecosystem that combines sequencing, informatics, and member reporting to enable early risk detection and personalized prevention.FinansavisenIllumina advances preventive genomics through strategic consortium with Veritas GeneticsIllumina announced a strategic collaboration with Veritas Genetics to develop a consortium aimed at incorporating preventive genomics into routine healthcare using population-scale whole-genome sequencing. The partnership will focus on integrating genomic data into health services in the United States and globally, supporting research, drug development, and clinical trials.PR NewswireIllumina advances preventive genomics through strategic consortium with Veritas GeneticsIllumina announced a strategic collaboration with Veritas Genetics (Powered By Fuze Health) to form a consortium aimed at integrating population-scale whole-genome sequencing into everyday healthcare through health insurance plans in the United States and other global markets. The partnership combines Illumina's sequencing and informatics technologies—including WGS and DRAGEN analysis—with Veritas' myGenome reporting, clinical interpretation, and genetic counseling services to enable earlier detection of hereditary cancer, cardiometabolic disease, and medication response risks. The initiative seeks to shift healthcare from reactive treatment to proactive prevention by delivering actionable genomic insights connected to appropriate clinical interventions.GenomeWebIllumina, Veritas Genetics Form Preventive Genomics ConsortiumIllumina announced on Monday the formation of a consortium with Veritas Genetics, part of Fuze Health, to launch an opt-in preventive genomics program in the US and other global markets. The program will provide whole-genome sequencing with actionable genomic insights, integrated care pathways including confirmatory testing, specialist referrals, and genetic counseling. The collaboration aims to generate a consented clinical-genomics dataset while leveraging Illumina's sequencing and informatics capabilities alongside Veritas's patient-ready reporting and clinical interpretation services.VeritasintVeritas Genetics acquires qGenomics to expand its footprint in rare diseases and perinatalVeritas Genetics has acquired qGenomics, a leader in carrier screening and rare disease diagnostics, to expand its clinical genomics portfolio. The acquisition enables Veritas to launch its own carrier screening solution, qCarrier, later in 2025, while qGenomics' founders have reinvested into Veritas' holding vehicle. This deal follows the December 2024 acquisition of NIMGenetics as part of Veritas' strategy to consolidate genomic-driven healthcare services under a single brand.SignalbaseqGenomics Acquired by Veritas GeneticsVeritas Genetics has acquired qGenomics, a Barcelona-based biotech company specializing in genomics diagnostics, for an undisclosed amount. The acquisition integrates qGenomics' diagnostic platforms, clinical expertise, and European market presence into Veritas Genetics' expanding genomics operations. The combined entity is expected to drive innovation in precision medicine and offer a broader spectrum of advanced genomic diagnostic solutions globally.InvestorsinhealthcareSpain: Veritas Genetics reaches agreement for full acquisition of NIMGeneticsVeritas Genetics, a Spain-based company within the LetsGetChecked group, announced the acquisition of NIMGenetics, a Spain-based multinational biotech company specializing in clinical genetic diagnostics. NIMGenetics is a portfolio company of London-based LetsGetChecked.VeritasintVeritas Genetics reaches an agreement with Apposite Capital and other shareholders, for the full acquisition of NIMGenetics, leading the future of medical geneticsVeritas Genetics, a LetsGetChecked company, has reached an agreement with Apposite Capital and other shareholders to fully acquire NIMGenetics, a leading clinical genetic diagnostics company. The acquisition combines NIMGenetics' expertise in clinical diagnostics and advanced genetic panels with Veritas Genetics' international research capabilities and technological infrastructure, supported by the LetsGetChecked group. Both companies are committed to ensuring service continuity while gradually integrating operations, with a focus on expanding capabilities in oncology, rare diseases, and perinatal and reproductive medicine.PR NewswireVeritas Genetics at the forefront of genomic screening with new studies presented at the European Society of Human Genetics Conference - ESHG 2024Veritas Genetics will present two pioneering genomic screening studies at the European Society of Human Genetics Conference 2024 in Berlin from June 1-4, including a newborn screening study analyzing 800 newborns in Spain and an elective genomic screening study covering 1,300 healthy individuals. The company will also showcase its polygenic risk assessment service myHealthScore, which evaluates genetic risk for common multifactorial diseases. Veritas, which joined the Letsgetchecked group in March 2022, continues to expand its preventive medicine and genomic diagnostics portfolio globally.AmericordbloodAmericord Partners with Veritas Genetics for…Americord Registry has partnered with Veritas Genetics, a LetsGetChecked-owned company, to offer newborn whole-genome screening to Americord families, which provide cord blood, cord tissue, placental tissue and exosome banking. The myNewborn test screens for more than 390 genetic conditions and is ordered by a healthcare professional for healthy or asymptomatic newborns and children in their first year.